Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411786 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02411786 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 40 participants.
The verdict
NCT02411786, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a vaccine called pTVG-AR can enhance the participant's immune response against prostate cancer.
Interventions
- BIOLOGICAL pTVG-AR
- BIOLOGICAL gm-csf
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-08-24 |
| Est. Completion | 2020-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411786
The ClinicalTrials.gov registry entry for NCT02411786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pTVG-AR is the first listed.
NCT02411786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411786 about?
NCT02411786 is a clinical study titled "A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF". The purpose of this study is to determine if a vaccine called pTVG-AR can enhance the participant's immune response against prostate cancer.
What is the current status of trial NCT02411786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-08-24. Estimated completion is 2020-11-28.
What interventions are being tested in trial NCT02411786?
The interventions under investigation include: pTVG-AR (BIOLOGICAL), gm-csf (BIOLOGICAL).
Who is sponsoring clinical trial NCT02411786?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.